Processa Pharmaceuticals Issues Letter to Shareholders

HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage...

Related Keywords

Processa Ngcs ,Bret Shapiro ,Patrick Lin ,Dear Processa Pharmaceuticals Shareholders ,Straits Research ,Processa Pharmaceuticals ,Optimus Oncology Initiative ,Company Contact ,Stable Financial Affairs ,Processa Pharmaceuticals Inc ,Company Next Generation Chemotherapy ,Processa Team ,Nasdaq ,Pharmaceuticals Inc ,Business Development Opportunities ,Processa Pharmaceuticals Shareholders ,Regulatory Science Approach ,Project Optimus Oncology Initiative ,Optimal Dosage Regimen ,New Chemical Entities ,Project Optimus ,Financial Affairs ,Business Development ,Forward Looking Vision ,Nexperienced Team ,Diversified Pipeline ,Regarding Processa ,Processa Regulatory Science Approach ,Optimal Dosage Regimens ,Optimus Oncology ,Next Generation Capecitabine ,Next Generation Gemcitabine ,Next Generation Irinotecan ,More Information ,Nasdaq Pcsa ,Nc ,Clinical Stage ,Pharmaceutical Company ,Next Generation ,Hemotherapeutic Drugs ,Eo George Ng ,